PJ004 / PEG-BIO Biopharm - LARVOL DELTA

Efficacy and Safety of Pegylated Peptide Agonist of Thrombopoietin Receptor (PN20) in Secondary Prevention of Chemotherapy-Induced Thrombocytopenias: A Multicenter, Single Arm, Phase Ib Trial (ASH 2024) - P1 | "This ongoing study is expected to provide a basis for the dosage selection of PN20 for CIT patients. In addition, a phase Ib clinical trial of PN20 for the treatment of primary immune thrombocytopenia (ITP) is also currently underway."

Clinical • P1 data • Biliary Cancer • Colorectal Cancer • Gastric Cancer • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Lung Cancer • Lymphoma • Oncology • Solid Tumor • Thrombocytopenia • Thrombocytopenic Purpura

Study of PN20 in Adult Patients with Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura